A randomized monocentric trial in febrile neutropenic patients: Ceftriaxone and gentamicin vs cefepime and gentamicin

Annals of Hematology

Volumn 81, Issue 1, 2002, Pages 37-43

  Cornely, Oliver A ^a   Bethe, U ^a   Seifert, H ^a   Breuer, K ^a   Schutt Gerowitt H ^a   Salzberger, B ^a   Schrappe, M ^a   Fatkenheuer G ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Cefepime; Ceftriaxone; Fever; Granulocytopenia; Neutropenia

Indexed keywords

AMPHOTERICIN B; CEFEPIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; PENICILLIN G; POLYMYXIN B; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMPIRICISM; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; PRIORITY JOURNAL; PRURITUS; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEVER; GENTAMICINS; HUMANS; NEUTROPENIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036943068     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-001-0392-9     Document Type: Article

References (24)

1. World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO offset publication no. 48. World Health Organization, Geneva
2. Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, Viot M, Soler-Michel P, Rollin C, Gres JJ (1998) Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 42:511-518
3. Böhme A, Shah PM, Stille W, Hoelzer D (1998) Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 3:324-330
4. Calandra T, Zinner SH, Viscoli C, de Bock R, Gaya H, Meunier F, Klastersky J, Glauser MP (1993) The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593
5. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
6. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 39:445-452
7. Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, Moreau P, Ladeb S, Nalet V, Rollin C, Gres JJ (1997) Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. Clin Infect Dis 24:41-51
8. Cornely OA, Bethe U, Salzberger B, Franzen C, Hartmann P, Steinmetz T, Fatkenheuer G, Seifert H, Diehl V, Schrappe M (2001) Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol 80:103-108
9. Cornely OA, Hiddemann W, Link H, Maschmeyer G, Glass B, Buchheidt D, Wilhelm M, Büchner T, Lipp T, Haas R, Heinemann V, Helmerking M, Adam D (1998) Interventional antimicrobial therapy in febrile neutropenic patients. PEG Study II. Haematol Blood Transf 93:1045-1049
10. de Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 120:834-844
11. Denning D, Fulle HH, Hellriegel KP (1987) Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. Onkologie 10:57-58
12. Elting LS, Bodey GP, Fainstein V (1986) Polymicrobial septicemia in the cancer patient. Medicine (Baltimore) 65:218-225
13. Gibson J, Johnson L, Snowdon L, Joshua D, Young G, MacLeod C, Sader C, Iland H, Vincent P, Kronenberg H (1993) Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 58:63-72
14. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 25:551-573
15. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS (1992) Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 15:S206-S215
16. Karthaus M, Egerer G, Kullmann KH, Ritter J, Jurgens H (1998) Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia. Eur J Clin Microbiol Infect Dis 17:501-504
17. Klastersky J (1988) Empiric antimicrobial therapy for febrile granulocytopenic cancer patients. Lessons from four EORTC trials. Acta Oncol 27:497-502
18. Link H, Blumenstengel K, Böhme A, Cornely OA, Kellner O, Nawrousian MR, Ostermann H, Schiel X, Wilhelm M (1999) Antimikrobielle Therapie von unerklärtem Fieber bei Neutropenie. Standardempfehlungen der Arbeitsgemeinschaft Infektiologie in der Hämatologie und Onkologie der Deutschen Gesellschaft für Hämatologie und Onkologie. Dtsch Med Wochenschr 124:S3-S8
19. Maschmeyer G, Braveny I (2000) Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 19: 915-925
20. Maschmeyer G, Link H, Hiddemann W, Meyer P, Helmerking M, Eisenmann E, Schmitt J, Adam D (1994) Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 73:2296-2304
21. Oppenheim BA (1998) The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 41 [Suppl D]: 7-11
22. Pizzo PA, Armstrong D, Bodey G, dePauw B, Feld R, Glauser M, Gaya H, Karp J, Klastersky J, Todeschini G, Verhoef J, Wade J, Young LS, Remington J (1990) From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 161:397-401
23. Wynd MA, Paladino JA (1996) Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother 30:1414-1424
24. Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C (1997) Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 41: 1704-708